logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8975239 B1

PDFFull Text
Date of Patent:
Mar. 10, 2015

Filed:

Aug. 06, 2013

Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine

Applicant:

Cyclacel Limited, London, GB;

Inventors:

Simon Richard Green, Dundee, GB;

Ruth Mackay, Dundee, GB;

Ian Neil Fleming, Angus, GB;

Assignee:

Cyclacel Limited, London, GB;

Attorneys:

Nelson Mullins Riley & Scarborough LLP

Cynthia L. Kanik

Adam J. Gastonguay

Primary Examiner:

Patrick Lewis

Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 31/405 (2006.01); A61K 31/245 (2006.01); A61K 31/353 (2006.01); A61K 31/502 (2006.01); A61K 31/706 (2006.01); A61K 31/7068 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/405 (2013.01); A61K 31/245 (2013.01); A61K 31/353 (2013.01); A61K 31/502 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A61K 45/06 (2013.01);
Abstract

A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.

Find Patent Forward Citations

Green, Simon. (2015). Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine (U.S. Patent No. 8975239). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/8975239

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…